Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
182 hedge funds and large institutions have $1.64B invested in Esperion Therapeutics in 2020 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 66 increasing their positions, 41 reducing their positions, and 23 closing their positions.
76% more capital invested
Capital invested by funds: $930M → $1.64B (+$711M)
74% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 23
61% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 41
34% more call options, than puts
Call options by funds: $47.6M | Put options by funds: $35.5M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
10% more funds holding
Funds holding: 165 → 182 (+17)
7.42% more ownership
Funds ownership: 108.33% → 115.76% (+7.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$26.8M |
| 2 |
Millennium Management
New York
|
+$18.6M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$14.8M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$14.1M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.35M |
| 2 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$7.02M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.91M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.96M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$4.56M |
ESPR Hedge Fund Activity: Q2 2020 in Review
182 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q2 2020, worth a combined $1.64B — up 76% from $930M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new ESPR positions and 23 closed out — a net gain of 17 holders — while 66 added to existing stakes and 41 trimmed.
The largest buyer was State Street, adding an estimated $26.8M. The largest seller was Balyasny Asset Management, cutting an estimated $8.35M.
- 182 institutional investors held Esperion Therapeutics (ESPR) as of Q2 2020, up from 165 in Q1 2020.
- Funds reported $1.64B of Esperion Therapeutics stock for Q2 2020, up 76% quarter-over-quarter.
- 40 funds opened new Esperion Therapeutics positions in Q2 2020 and 23 closed out, a net change of +17 holders.
- The largest Esperion Therapeutics buyer in Q2 2020 was State Street, an estimated $26.8M added.
- The largest Esperion Therapeutics seller in Q2 2020 was Balyasny Asset Management, an estimated $8.35M sold.
Based on aggregated 13F filings for Q2 2020.